The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND
Monoclonal antibodies against programmed cell death protein 1 (PD‐1) and programmed death ligand 1 (PD‐L1) are effective therapies in patients with non‐small cell lung cancer (NSCLC). Herein, the authors performed a systematic review investigating differences in the toxicities of PD‐1 and PD‐L1 inhibitors.
METHODS
An electronic literature search was performed of public databases (MEDLINE,...
BACKGROUNDThe last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real‐world trends in the use of systemic therapies and the impact on patient outcomes in the United States.
METHODSThe Surveillance, Epidemiology, and End Results–Medicare database was used to find patients diagnosed with SCLC between 1985 and 2005. The 1985‐1990...
BACKGROUND:Patients with extensive stage small cell lung cancer (SCLC) who develop disease progression with standard cisplatin‐based therapy are reported to have a poor overall prognosis. Irinotecan and paclitaxel are active as single agents and exhibit preclinical synergy in SCLC cell lines. A phase 2 study was conducted to evaluate this combination in patients with recurrent or refractory SCLC....
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.